A. Harstrick

10.7k total citations · 1 hit paper
128 papers, 8.2k citations indexed

About

A. Harstrick is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A. Harstrick has authored 128 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Oncology, 40 papers in Molecular Biology and 39 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A. Harstrick's work include Colorectal Cancer Treatments and Studies (33 papers), Cancer Treatment and Pharmacology (30 papers) and Testicular diseases and treatments (29 papers). A. Harstrick is often cited by papers focused on Colorectal Cancer Treatments and Studies (33 papers), Cancer Treatment and Pharmacology (30 papers) and Testicular diseases and treatments (29 papers). A. Harstrick collaborates with scholars based in Germany, United States and United Kingdom. A. Harstrick's co-authors include Yves Humblet, M. Mueser, David Khayat, Harry Bleiberg, Armando Santoro, David Cunningham, Chris Verslype, Ian Chau, Eric Van Cutsem and Salvatore Siena and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

A. Harstrick

126 papers receiving 7.9k citations

Hit Papers

Cetuximab Monotherapy and... 2004 2026 2011 2018 2004 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
    2004 3.9k citations A. Harstrick et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
A. Harstrick 5.6k 2.9k 1.9k 1.8k 1.0k 128 8.2k
Otilia Dalesio 4.4k 0.8× 3.9k 1.3× 1.5k 0.8× 1.4k 0.8× 846 0.8× 104 8.0k
Joseph P. Eder 8.2k 1.5× 3.2k 1.1× 3.4k 1.8× 1.6k 0.9× 1.1k 1.0× 178 12.2k
W. Heim 6.6k 1.2× 3.0k 1.0× 3.3k 1.7× 1.3k 0.7× 956 0.9× 23 10.1k
Gwen Fyfe 5.7k 1.0× 2.4k 0.8× 3.0k 1.6× 1.1k 0.6× 866 0.9× 13 9.0k
Lee S. Rosen 8.4k 1.5× 3.8k 1.3× 3.6k 1.9× 1.8k 1.0× 840 0.8× 232 12.1k
Min‐Hee Ryu 3.7k 0.7× 4.5k 1.5× 847 0.4× 2.4k 1.4× 762 0.7× 327 7.6k
Robert W. Ross 6.1k 1.1× 3.5k 1.2× 3.9k 2.0× 1.6k 0.9× 953 0.9× 61 11.1k
Napoleone Ferrara 5.7k 1.0× 2.4k 0.8× 3.6k 1.9× 1.2k 0.7× 889 0.9× 16 9.6k
Christopher R. Garrett 2.8k 0.5× 2.4k 0.8× 1.4k 0.7× 953 0.5× 769 0.8× 50 5.3k
Axel Hinke 5.6k 1.0× 3.1k 1.0× 906 0.5× 2.0k 1.2× 1.7k 1.6× 189 8.5k

Countries citing papers authored by A. Harstrick

Since Specialization
Citations

This map shows the geographic impact of A. Harstrick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Harstrick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Harstrick more than expected).

Fields of papers citing papers by A. Harstrick

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Harstrick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Harstrick. The network helps show where A. Harstrick may publish in the future.

Co-authorship network of co-authors of A. Harstrick

This figure shows the co-authorship network connecting the top 25 collaborators of A. Harstrick. A scholar is included among the top collaborators of A. Harstrick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Harstrick. A. Harstrick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Middleton, Mark R., Sanjeev Kumar, Jordi Rodón, et al.. (2016). Interim results from the completed first-in-human phase I dose escalation study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF, in patients with advanced solid tumors. Annals of Oncology. 27. vi115–vi115. 4 indexed citations
4.
Welt, Anja, Gϋnter von Minckwitz, C. Oberhoff, et al.. (2004). Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Annals of Oncology. 16(1). 64–69. 56 indexed citations
5.
Krause, Mechthild, Cordula Petersen, N. Pimentel, et al.. (2004). Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC. Radiotherapy and Oncology. 74(2). 109–115. 55 indexed citations
6.
Bojko, Peter, Anja Welt, Regina Schleucher, et al.. (2004). High-dose chemotherapy with autologous stem cell transplantation in patients with oligometastatic breast cancer. Bone Marrow Transplantation. 34(7). 637–643. 10 indexed citations
7.
Tewes, Mitra, N. Schleucher, W. Achterrath, et al.. (2003). Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study†. Annals of Oncology. 14(9). 1442–1448. 46 indexed citations
8.
Bojko, Peter, et al.. (1999). Thrombopoietin serum levels at the start of mobilization, collection, and transfusion of autologous peripheral blood stem cells. Journal of Clinical Apheresis. 14(2). 57–62. 2 indexed citations
9.
Harstrick, A., Andrea J. Gonzales, N. Schleucher, et al.. (1998). Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance. Anti-Cancer Drugs. 9(7). 625–634. 25 indexed citations
10.
Kollmannsberger, Christian, J. Beyer, Jean‐Pierre Droz, et al.. (1998). Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.. Journal of Clinical Oncology. 16(10). 3386–3391. 143 indexed citations
11.
Klaassen, U., A. Harstrick, Dirk Strumberg, Hans‐Joachim Wilke, & S. Seeber. (1998). Paclitaxel plus ifosfamide in advanced ovarian cancer. Anti-Cancer Drugs. 9(4). 359–362. 5 indexed citations
12.
Klaassen, U., Hans‐Joachim Wilke, A. Harstrick, et al.. (1998). Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: Results of a phase II study. Annals of Oncology. 9(1). 45–50. 13 indexed citations
13.
Vanhoefer, U., Wieland Voigt, Ralf A. Hilger, et al.. (1997). Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.. PubMed. 9(9). 485–94. 5 indexed citations
14.
Vanhoefer, U., Shousong Cao, A. Harstrick, S. Seeber, & Youcef M. Rustum. (1997). Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Annals of Oncology. 8(12). 1221–1228. 63 indexed citations
15.
Harstrick, A., Hans‐Joachim Wilke, Wilfried Eberhardt, et al.. (1996). A Phase I Dose Escalation Trial of Intravenous Treosulfan in Refractory Cancer. Oncology Research and Treatment. 19(2). 153–156. 20 indexed citations
16.
Bokemeyer, Carsten, A. Harstrick, & Hans‐Joachim Schmoll. (1994). Treatment of Adult Soft-Tissue Sarcomas with Dose-Intensified Chemotherapy and Haematopoietic Growth Factors. Oncology Research and Treatment. 17(3). 216–225. 4 indexed citations
17.
Wilke, H., P. Preusser, M. Stahl, et al.. (1994). Phase II Study with Folinic Acid, Etoposide, 5-Fluorouracil and Cisplatin (FLEP) for Advanced Gastric Cancer. Oncology Research and Treatment. 17(2). 154–157.
18.
Harstrick, A., et al.. (1993). Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines. European Journal of Cancer. 29(7). 1000–1002. 26 indexed citations
19.
Stahl, M., H. Wilke, P. Preusser, et al.. (1991). Etoposide, Leukovorin and 5-Fluorouracil (ELF) in Advanced Gastric Carcinoma – Final Results of a Phase-II Study in Elderly Patients or Patients with Cardiac Risk. Oncology Research and Treatment. 14(4). 314–318. 5 indexed citations
20.
Schmoll, Hans‐Joachim, et al.. (1990). Modulation of cytotoxic drug activity by dipyridamole. Cancer Treatment Reviews. 17. 57–65. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Otilia Dalesio Breakdown of academic impact, for papers by Joseph P. Eder Breakdown of academic impact, for papers by W. Heim Breakdown of academic impact, for papers by Gwen Fyfe Breakdown of academic impact, for papers by Lee S. Rosen Breakdown of academic impact, for papers by Min‐Hee Ryu Breakdown of academic impact, for papers by Robert W. Ross Breakdown of academic impact, for papers by Napoleone Ferrara Breakdown of academic impact, for papers by Christopher R. Garrett Breakdown of academic impact, for papers by Axel Hinke
Rankless by CCL
2026